The miR‐34a has been identified to be up‐regulated in different kinds of liver diseases, including non‐alcoholic steatohepatitis (NASH) and ALD but down‐regulated in hepatocellular carcinoma.18, 20, 38 Previous studies have linked p53 to miR‐34a in high‐fat diet‐induced NASH model as well as in human patients with non‐alcoholic liver diseases.20, 39 The miR‐34a‐mediated liver disease progression was through controlling protein acetylation via inhibiting the expression of Sirt1, also known as NAD‐dependent deacetylase sirtuin‐1. This evidence concerns the gene TP53 and metabolic dysfunction-associated steatohepatitis.